Two case reports of brain metastases in patients with pancreatobiliary neuroendocrine carcinoma.
Brain metastasis
Chemotherapy
Pancreatobiliary neuroendocrine carcinoma
Radiation therapy
Surgical resection
Journal
Clinical journal of gastroenterology
ISSN: 1865-7265
Titre abrégé: Clin J Gastroenterol
Pays: Japan
ID NLM: 101477246
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
13
08
2020
accepted:
10
10
2020
pubmed:
24
10
2020
medline:
29
6
2021
entrez:
23
10
2020
Statut:
ppublish
Résumé
Brain metastases are extremely rare in patients with pancreatobiliary neuroendocrine caricnoma (PB-NEC). In this case report, we report two rare cases of brain metastases in patients with PB-NEC. Each patient was diagnosed with brain metastases five and ten months after the initial diagnosis of PB-NEC. It is noteworthy that the serum tumor marker neuron-specific enolase (NSE) or pro-gastrin-releasing peptide (Pro-GRP) was elevated, although the primary and metastatic lesions other than in the brain were under control with systemic chemotherapy. Moreover, the patients complained of no neurological symptoms until they were diagnosed with brain metastases. Although the incidence of brain metastases of PB-NEC is exceedingly low, it is important to keep in mind the possibility of brain metastases during the course of treatment for PB-NEC. In addition, we discuss a strategy of treatment and screening for brain metastases of PB-NEC in this case report.
Identifiants
pubmed: 33095423
doi: 10.1007/s12328-020-01270-w
pii: 10.1007/s12328-020-01270-w
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
386-390Références
Sasaki T, Takamatsu M, Furukawa T, et al. Clinicopathological analysis of biliary neuroendocrine neoplasms and chemotherapy for biliary neuroendocrine carcinoma. Tando. 2020;34:153–62.
Korse CM, Taal BG, van Velthuysen ML, et al. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer. 2013;49:1975–83.
doi: 10.1016/j.ejca.2012.12.022
Kang H, O’Connell JB, Leonardi MJ, et al. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis. 2007;22:183–9.
doi: 10.1007/s00384-006-0145-2
Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E, et al. Trends in incidence of neuroendocrine neoplasms in Norway: a report of 16,075 cases from 1993 through 2010. Neuroendocrinology. 2017;104:1–10.
doi: 10.1159/000442207
Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: A nationwide survey analysis. J Gastroenterol. 2015;50:58–64.
doi: 10.1007/s00535-014-0934-2
Fujii M, Saito H, Shiode J. Rare case of a gallbladder neuroendocrine carcinoma. Clin J Gastroenterol. 2019;12:38–45.
doi: 10.1007/s12328-018-0883-z
Modlin IM, Shapiro MD, Kidd M. An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg. 2005;29:92–101.
doi: 10.1007/s00268-004-7443-z
Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.
doi: 10.1200/JCO.2007.15.4377
Chen C, Wang L, Liu X, et al. Gallbladder neuroendocrine carcinoma: report of 10 cases and comparision of clinicopathologic features with gallbladder adenocarcinoma. Int J Clin Exp Pathol. 2015;8:8218–26.
pubmed: 26339390
pmcid: 4555718
Garcia Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103:186–94.
doi: 10.1159/000443172
Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: Guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19:162–74.
doi: 10.1093/neuonc/now241
Kotecha R, Zimmerman A, Murphy ES, et al. Management of brain metastasis in patients with pulmonary neuroendocrine carcinomas. Technol Cancer Res Treat. 2016;15:566–72.
doi: 10.1177/1533034615589033
Prayongrat A, Tao R, Allen PK, et al. Outcomes of stereotactic radiosurgery of brain metastases from neuroendocrine tumors. Neurooncol Pract. 2018;5:37–45.
pubmed: 31385968
Reveiz L, Rueda JR, Cardona AF. Chemotherapy for brain metastases from small cell lung cancer. Cochrane Database Syst Rev. 2012;6:CD007464.
Franchino F, Rudà R, Soffietti R. Mechanisms and therapy for cancer metastasis to the brain. Front Oncol. 2018;8:161.
doi: 10.3389/fonc.2018.00161
Kamath SD, Kumthekar PU. Immune checkpoint inhibitors for the treatment of central nervous system (CNS) metastatic disease. Front Oncol. 2018;8:414.
doi: 10.3389/fonc.2018.00414
Yu LY, Tang J, Zhang CM, et al. New immunotherapy strategies in breast cancer. Int J Environ Res Public Health. 2017;14:68.
doi: 10.3390/ijerph14010068
Farber SH, Tsvankin V, Narloch JL, et al. Embracing rejection: immunologic trends in brain metastasis. Oncoimmunology. 2016;5:e1172153.
doi: 10.1080/2162402X.2016.1172153
Johanns T, Waqar SN, Morgensztern D. Immune checkpoint inhibition in patients with brain metastases. Ann Transl Med. 2016;4(Suppl 1):S9.
doi: 10.21037/atm.2016.09.40
Leal T, Chang JE, Mehta M, et al. Leptomeningeal metastasis: challenges in diagnosis and treatment. Curr Cancer Ther Rev. 2011;7:319–27.
doi: 10.2174/157339411797642597
Venur VA, Ahluwalia MS. Novel therapeutic agents in the management of brain metastases. Curr Opin Oncol. 2017;29:395–9.
doi: 10.1097/CCO.0000000000000393
Lin NU. Targeted therapies in brain metastases. Curr Treat Options Neurol. 2014;16:276.
doi: 10.1007/s11940-013-0276-z
Lin J, Jandial R, Nesbit A, et al. Current and emerging treatments for brain metastases. Oncology (Williston Park). 2015;29:250–7.
Soffietti R, Trevisan E, Rudà R. Targeted therapy in brain metastasis. Curr Opin Oncol. 2012;24:679–86.
doi: 10.1097/CCO.0b013e3283571a1c
Esmaeilzadeh M, Majlesara A, Faridar A, et al. Brain metastasis from gastrointestinal cancers: a systematic review. Int J Clin Pract. 2014;68:890–9.
doi: 10.1111/ijcp.12395
NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer Version 2. 2018. https://www2.tri-kobe.org/nccn/guideline/lung/english/small.pdf . Accessed 24 May 2020.
Krug S, Teupe F, Michl P, et al. Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome. BMC Cancer. 2019;19:362.
doi: 10.1186/s12885-019-5559-7